CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc. Berne S.E.

Stocks

RV6

US1598641074

Biotechnology & Medical Research

End-of-day quote Berne S.E. 16/09/2026			5-day change	1st Jan Change
226.97 ^CHF	+2.07%		+0.87%	-

09:24pm	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
08:25pm	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT

All News

Mentions Relevance

09:24pm	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
08:25pm	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT
08:01pm	Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines	BU
09-16	Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says	MT
09-15	Charles River Laboratories International, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:40 AM
09-14	Charles River Laboratories International, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM
09-11	Charles River Laboratories to Present at Morgan Stanley and Baird Conferences	BU
09-11	Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating	MT
09-09	Charles River Modernizes Endosafe(R) Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite	AQ
09-08	Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite	CI
09-08	Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite	BU
08-21	Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing	MT
08-20	Charles River, Medigen Partner on Multivalent Enterovirus Vaccine	MT
08-20	Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing	BU
08-14	Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing	MT
08-10	TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating	MT
08-10	Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating	MT
08-07	Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing	MT
08-06	Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220	MT
08-06	RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating	MT
08-06	Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating	MT
08-06	JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180	MT
08-06	Top Midday Gainers	MT
08-05	Charles River Laboratories International, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI